Becton, Dickinson and Company (BDX) Projected to Post Earnings on Thursday

Becton, Dickinson and Company (NYSE:BDX) is expected to be posting its quarterly earnings results before the market opens on Thursday, February 6th. Analysts expect Becton, Dickinson and Company to post earnings of $3.00 per share and revenue of $5.13 billion for the quarter. Becton, Dickinson and Company has set its FY 2025 guidance at 14.250-14.600 EPS and its FY25 guidance at $14.25-14.60 EPS.Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, beating the consensus estimate of $3.77 by $0.04. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The firm had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same period last year, the business posted $3.42 EPS. Becton, Dickinson and Company’s quarterly revenue was up 6.9% on a year-over-year basis. On average, analysts expect Becton, Dickinson and Company to post $14 EPS for the current fiscal year and $16 EPS for the next fiscal year.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock opened at $246.85 on Thursday. The firm has a market capitalization of $71.59 billion, a PE ratio of 41.56, a P/E/G ratio of 1.72 and a beta of 0.39. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $250.91. The firm’s 50-day simple moving average is $229.10 and its 200 day simple moving average is $233.46. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be paid a dividend of $1.04 per share. The ex-dividend date is Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.69%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 70.03%.

Becton, Dickinson and Company announced that its board has approved a share repurchase program on Tuesday, January 28th that authorizes the company to buyback 10,000,000 shares. This buyback authorization authorizes the medical instruments supplier to buy shares of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s management believes its stock is undervalued.

Insider Activity

In related news, EVP Roland Goette sold 4,483 shares of Becton, Dickinson and Company stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $221.01, for a total transaction of $990,787.83. Following the transaction, the executive vice president now directly owns 24,345 shares of the company’s stock, valued at $5,380,488.45. The trade was a 15.55 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP David Shan sold 500 shares of Becton, Dickinson and Company stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $240.00, for a total transaction of $120,000.00. Following the completion of the transaction, the executive vice president now directly owns 5,741 shares in the company, valued at $1,377,840. This represents a 8.01 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 9,844 shares of company stock valued at $2,210,716. 0.36% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have issued reports on BDX shares. Piper Sandler raised their price target on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research note on Tuesday. StockNews.com cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $283.00.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.